A new human-in-the-loop AI framework has identified promising CAR T therapy targets in weeks instead of years, with early lab ...

The collaboration will see the companies gather and analyse data from many patient samples.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented data today at the T-cell ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients ...

CAR T-cell therapy genetically alters a patient's immune cells to fight certain cancers like lymphoma and leukemia.

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today announced its participation in the 8th T-Cell Engager Therapeutics Summit and the BIO ...

Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

Immunotherapy has transformed cancer treatment by significantly improving patient outcomes through treatments such as immune checkpoint inhibitors (ICIs) and adoptive T-cell therapy (ACT) 1. While ...

AbCellera will conduct discovery and early-stage research activities on two initial programmes.